Alembic Pharma gets USFDA nod to Diltiazem Hydrochloride ER Capsules to treat hypertension
Written By : Farhat Nasim
Published On 2024-10-22 08:50 GMT | Update On 2024-10-22 08:50 GMT
Advertisement
Mumbai: Drug maker Alembic Pharmaceuticals Ltd has recently announced that it has received final approval from the United States Food and Drug Administration (USFDA) for the abbreviated new drug application (ANDA) Diltiazem Hydrochloride extended-release capsules of strengths 120 mg, 180 mg, and 240 mg.
The approved ANDA is therapeutically equivalent to the reference listed drug, Dilacor XR Extended-Release Capsules (120 mg, 180 mg, and 240 mg), manufactured by Allergan Sales LLC, the company said in a statement.
Diltiazem Hydrochloride Extended-Release Capsules USP are prescribed for hypertension management and can be used alone or alongside other antihypertensive drugs, like diuretics. Additionally, they are indicated for managing chronic stable angina.
Read also: Alembic Pharma successfully completes USFDA inspection at Panelav Oncology formulation facility
According to IQVIA, the estimated market size for Diltiazem Hydrochloride Extended-Release Capsules USP (120 mg, 180 mg, and 240 mg) is $28.2 million for the twelve-month period ending June 2024.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.